Breast Cancer Overdiagnosis Rate Falls Below 5% in Re-Analysis of Major Mammography Trials

On September 14, 2026, a comprehensive re-evaluation of all eight major randomized mammography trials published in the Journal of the National Cancer Institute overturned one of the most persistent statistical fears in oncology. The study concluded that the rate of breast cancer overdiagnosis—the detection of tumors that would never have caused symptoms or threatened a woman's health during her lifetime—sits below 5 percent. This marks a sharp and highly consequential drop from historical estimates that ranged between 30 and 50 percent, fundamentally altering how the medical community views the risks of routine screening.[1][2][6]

The discrepancy between the new findings and the historical estimates stems from how early trial data was interpreted before long-term follow-up was complete. When a population begins a screening program, the number of cancer diagnoses immediately spikes because tumors are found much earlier than they would be through physical symptoms alone. "Over time, this should be followed by a drop, as some of these cancers would otherwise have been diagnosed later," explained Elsebeth Lynge, a professor emerita of public health at the University of Copenhagen. That natural ebb and flow of detection rates requires decades of observation to fully stabilize.[2]

If researchers do not account for that compensatory drop, the initial spike in detection looks like a permanent surplus of cancers. The data is further muddied by "exit screening"—a phenomenon where women assigned to the unscreened control group undergo mammography after the official trial period ends. Failing to adjust for these two factors creates a statistical illusion that drove the 30 to 50 percent estimates. Those inflated figures subsequently shaped international screening guidelines and the risk disclosures provided to patients over the last 20 years, causing widespread anxiety about the potential harms of early detection.[1][2]

To separate the true signal from the statistical noise, the research team—spanning the University of Southern Denmark, Queen Mary University of London, the University of Copenhagen, and the American Cancer Society—applied a unified reference framework. They benchmarked the historical trial data, some of which dates back to the 1970s and 1980s, against the Funen screening program in Denmark. Because organized mammography was introduced in Funen 17 years earlier than in other Danish regions, it provided a pristine, long-term baseline for how breast cancer incidence rates behave over a prolonged period of continuous screening.[3][6]

The researchers extracted data across 52 distinct timepoints from the eight randomized trials, tracking both invasive breast cancer and ductal carcinoma in situ. They then compared the observed relative proportions of cancer in the trials to the expected patterns derived from the Danish population data. By standardizing the timeline and adjusting for the exit screening artifacts that plagued earlier analyses, the team was able to reconstruct a highly accurate picture of what actually happened to the women enrolled in those foundational studies.[1][5]

The alignment between the corrected trial data and the real-world baseline was striking. The excess number of breast cancer cases detected in the randomized trials closely matched what would be expected in the Danish screening population, where overdiagnosis is strictly calculated at below 5 percent. "When interpreted in their full temporal context, randomized trial data are consistent with overdiagnosis of less than five percent, rather than with estimates nearing 50 percent," stated Matejka Rebolj, a senior epidemiologist at Queen Mary University of London.[3][6]

The findings offer immediate clarity for clinical counseling and patient anxiety. Women evaluating screening options have historically faced the daunting prospect that a positive mammogram might lead to unnecessary biopsies, radiation, or surgery for a lesion that posed no actual threat. "Randomized trials have often been cited as evidence that overdiagnosis is a substantial problem," noted lead researcher Sisse Helle Njor of the University of Southern Denmark. "Our study shows that this interpretation is not as straightforward as it may seem."[2][6]

With the statistical noise cleared, the risk-benefit calculus for mammography shifts decisively. The confirmation that more than 95 out of 100 screen-detected cancers represent genuine clinical findings means medical boards can refine their guidance without the shadow of massive overdiagnosis. Future policy discussions will no longer need to weigh the proven mortality benefits of early detection against an inflated risk of unnecessary intervention, allowing physicians to recommend screening with greater confidence and providing patients with the reassurance they need to participate.[4]